Skip to main content
Clinical Trials/ChiCTR2200062413
ChiCTR2200062413Not yet recruitingPhase 4

瑞马唑仑与丙泊酚镇静作用 BIS 关联指标的比较分析

自筹1 site in 1 country30 target enrollmentStarted: August 1, 2022Last updated:

Trial Snapshot

Phase
Phase 4
Status
Not yet recruiting
Sponsor
Enrollment
30
Locations
1
Primary Endpoint
脑电双频指数

Study Overview

Brief Summary

通过收集瑞马唑仑 / 丙泊酚联合阿芬太尼用于结肠镜息肉切除术患者的 EEG,研究 EMG 与 SEF95%与瑞马唑仑及丙泊酚 BIS 值的相关性。

Study Design

Study Type
干预性研究
Primary Purpose
随机平行对照

Eligibility Criteria

Ages
18 to 80 (—)
Sex
All

Inclusion Criteria

  • 手术时间 20min~1h;
  • BMI 18.5~23.9 kg/m2;

Exclusion Criteria

  • 饱胃、反流误吸风险高的患者;
  • 对苯二氮卓类及阿片类药物过敏者;
  • 24 小时内有服用镇静、镇痛或抗抑郁药物者;
  • 近期参加其他临床研究;

Arms & Interventions

AP 组

阿芬太尼 10μg/kg+丙泊酚 2mg/kg

AR 组

阿芬太尼 10μg/kg+瑞马唑仑 0.15mg/kg

Outcomes

Primary Outcomes

脑电双频指数

肌电信号

95%频谱边缘频率

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
自筹

Study Sites (1)

Loading locations...

Similar Trials